Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi
Mitomu
M
Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.
Kawakami
Koji
K
Puri
Raj K
RK
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001427:Bacterial Toxins / Q000494:pharmacology*; D001667:Binding, Competitive; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003603:Cytotoxins / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005098:Exotoxins / Q000737:chemistry / Q000494:pharmacology*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy; D006801:Humans; D018793:Interleukin-13 / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D053661:Interleukin-13 Receptor alpha1 Subunit; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011485:Protein Binding; D011549:Pseudomonas / Q000378:metabolism*; D018123:Receptors, Interleukin / Q000378:metabolism*; D053660:Receptors, Interleukin-13; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000494:pharmacology*; D013997:Time Factors
D000970:Antineoplastic Agents; D001427:Bacterial Toxins; D003603:Cytotoxins; D005098:Exotoxins; C521502:IL13-PE38; C494897:IL13E13K-PE38 protein; C508181:IL13RA1 protein, human; C508183:Il13ra1 protein, mouse; D018793:Interleukin-13; D053661:Interleukin-13 Receptor alpha1 Subunit; D018123:Receptors, Interleukin; D053660:Receptors, Interleukin-13; D011993:Recombinant Fusion Proteins